Association between post-operative hPG80 (circulating progastrin) detectable level and worse prognosis in glioblastoma

L Doucet; A Cailleteau; L Vaugier; C Gourmelon; M Bureau; C Salaud; V Roualdes; E Samarut; M Aumont; M Zenatri; D Loussouarn; V Quillien; F Bocquet; L Payen-Gay; D Joubert; A Prieur; M Robert; J-S Frenel

doi:10.1016/j.esmoop.2023.101626

Association between post-operative hPG₈₀ (circulating progastrin) detectable level and worse prognosis in glioblastoma

ESMO Open. 2023 Oct;8(5):101626. doi: 10.1016/j.esmoop.2023.101626. Epub 2023 Sep 13.

Authors

L Doucet¹, A Cailleteau², L Vaugier², C Gourmelon³, M Bureau³, C Salaud⁴, V Roualdes⁴, E Samarut⁴, M Aumont², M Zenatri³, D Loussouarn⁵, V Quillien⁶, F Bocquet⁷, L Payen-Gay⁸, D Joubert⁹, A Prieur⁹, M Robert³, J-S Frenel³

Affiliations

¹ Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France. Electronic address: Ludovic.doucet@ico.unicancer.fr.
² Department of Radiation Therapy, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.
³ Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.
⁴ Department of Neurosurgery, Centre Hospitalo-Universitaire, Nantes, France.
⁵ Department of Pathology, Centre Hospitalo-Universitaire, Nantes, France.
⁶ Department of Biology, Centre Eugene Marquis, Rennes, France.
⁷ Data Factory & Analytics, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.
⁸ Department of Biochemistry, Molecular Oncology and Transfer Unit, Cancer Institute of Hospices Civils De Lyon, Pierre Benite, France.
⁹ Biodena Care, Grabels, France.

Abstract

Background: Patients with glioblastomas have a dismal prognosis, and there is no circulating predictive or prognostic biomarker. Circulating progastrin, hPG₈₀, is a tumor-promoting peptide present in the blood of patients with various cancers that has been shown to have prognostic value. We evaluated the prognostic value of plasma hPG₈₀ in patients with isocitrate dehydrogenase-wild type glioblastoma after surgery.

Patients and methods: A multicentric retrospective study in glioblastoma patients treated with standard radio-chemotherapy was conducted. The hPG₈₀ levels were measured in plasma EDTA samples collected after surgery with an ELISA DxPG80.lab kit (Biodena Care, Montpellier, France), which has a detection threshold of 1.2 pM. The relationship between post-operative hPG₈₀ plasma levels, in combination with other known prognostic factors, and patients' progression-free survival (PFS) and overall survival (OS) was evaluated.

Results: Sixty-nine patients were assessable. Plasma samples were collected after tumor biopsy (B), partial resection (PR), and complete resection (CR) for 22, 25, and 22 patients, respectively. At a median concentration of 5.37 pM (interquartile range 0.00-13.90 pM), hPG₈₀ was detected in 48 (70%) patients (hPG₈₀+). CR was associated with significant lower values of hPG₈₀ levels: the median value was 0.7 versus 9.1 pM for PR (P = 0.02) and 8.3 pM for B (P = 0.004). The hPG₈₀ detection rate was also significantly lower: 50% (CR) versus 72% (PR) versus 86% (B) (P = 0.005). The median follow-up was 39 months [22.4 months-not reached]. hPG₈₀ post-operative detection was associated with numerically shorter PFS (6.4 versus 9.4 months, P = 0.13) and OS (14.5 versus 20.9 months, P = 0.11). In multivariate analysis, hPG₈₀ was a prognostic factor for OS (P = 0.034).

Conclusions: Circulating hPG₈₀ could serve as a new prognostic biomarker after surgery in patients with glioblastoma treated with radio-chemotherapy.

Keywords: biomarker; glioblastoma; hPG(80); prognostic.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Glioblastoma* / drug therapy
Glioblastoma* / surgery
Humans
Prognosis
Retrospective Studies

Substances

big gastrin
Biomarkers